¿CÓMO FUNCIONA EL DIU DE PROGESTINA? • El DIU de progestina es un tubo plástico con forma de T que permanece dentro de su útero. Contiene una. Intrauterine device (IUD) with progestogen, sold under the brand name Mirena among others, is a intrauterine device that releases the hormone levonorgestrel. Several women use the levonorgestrel-releasing intrauterine system, which is called in the market as Mirena®. This report evaluated the possibility of inserting .
|Published (Last):||19 August 2013|
|PDF File Size:||7.12 Mb|
|ePub File Size:||14.11 Mb|
|Price:||Free* [*Free Regsitration Required]|
Intrauterine device IUD with progestogensold under the brand name Mirena among others, is a intrauterine device that releases the hormone levonorgestrel.
Hormonal IUDs – Wikipedia
Side effects include irregular periods, benign ovarian cystspelvic pain, and depression. In addition to birth controlhormonal IUD are used for mirdna and treatment of:. After insertion, Mirena is officially sold as effective for up to five years, although several studies have shown that it remains effective through seven years. The hormonal IUD is a long-acting reversible contraceptiveand is considered one of the most effective forms of birth control.
The first year failure rate for the hormonal IUD is 0. The hormonal IUD is considered to be more effective than other common forms of reversible contraception, such as the birth control pillbecause it requires little action by the user after insertion.
If medication regimens for contraception are not followed precisely, the method becomes less effective. IUDs require no daily, weekly, or monthly regimen, dispositjvo their typical use failure rate is therefore the same as their perfect use failure rate. In women with bicornuate uterus and in need of contraception, two IUDs are generally applied one in each horn due to lack of evidence diispositivo efficacy with only one IUD.
Progestogen-only contraceptives such as an IUD are not believed to affect milk supply or infant growth. When using Mirena, about 0. There are conflicting recommendations about use of Mirena while breastfeeding. FDA does not recommend any hormonal method, including Mirena, as a first choice of contraceptive for nursing mothers. It also reports concerns about potential effects on the infant’s liver and brain development in the first six weeks postpartum.
However, it recommends offering Mirena as a contraceptive option beginning at six weeks postpartum even to nursing women.
According to a evaluation of the studies performed on progestin-only birth control by the International Agency for Disposjtivo on Cancer, there is some evidence that progestin-only birth control reduces the risk of endometrial cispositivo.
The IARC concluded that there is no evidence progestin-only birth control increases the risk of any cancer, though the available studies were too small to be definitively conclusive. Progesterone is a hormone in the endometrium that counteracts estrogen driven growth. Estrogen and progesterone have an antagonistic relationship.
Estrogen promotes the growing of endometrial lining, while progesterone limits it. Tumors formed are correlated with insufficient progesterone and excess estrogen. No evidence has been identified to suggest Mirena affects bone mineral density BMD.
The authors of the study said their results were predictable, since it is well established that the main factor responsible for bone loss in women is hypoestrogenismand, in agreement with previous reports, they found estradiol levels in Mirena users to be normal. The hormonal IUD is a small ‘T’-shaped piece of plastic, which contains levonorgestrela type of progestin.
This declines to a rate of 14 micrograms per day after five years, which is still in the range of clinical effectiveness. Skyla releases 14 micrograms per day and declines to five micrograms per day after three years. Most of the drug stays inside the uterus, and only a small amount is absorbed into the rest of the body. The hormonal IUD is inserted in a similar procedure to the nonhormonal copper IUD, and can only be inserted by a qualified medical practitioner.
It is also recommended that patients be tested for gonorrhea and chlamydia prior to insertion, as a current STI at the time of insertion can increase the risk of pelvic infection. During the insertion, the vagina is held open with a speculumthe same device used during a pap smear. The string allows physicians and patients to check to ensure the IUD is still in place and enables easy removal of the device.
Insertion can be performed immediately postpartum and post-abortion if no infection has occurred. Removal of the device should also be performed by a qualified medical practitioner. After removal, fertility will return to previous levels relatively quickly. Levonorgestrel is a progestogeni. The hormonal IUD’s primary mechanism of action is to prevent fertilization. Numerous studies have demonstrated that IUDs primarily prevent fertilization, not implantation.
Antonio Scommenga, working at the Michael Reese Hospital in Chicago, discovered that administering progesterone inside the uterus could have contraceptive benefits.
This IUD had a short, 1-year lifespan and never achieved widespread popularity. Following this relative lack of success, Dr. Luukkainen replaced the progesterone with the hormone levonorgestrel to be released over a five-year period, creating what is now Mirena. The Mirena IUD was studied for safety and efficacy in two clinical trials in Finland and Sweden involving 1, women who were all between 18 and 35 years of age at the beginning of the trials.
The trials included predominantly Caucasian women who had been previously pregnant with no history of ectopic pregnancy or pelvic inflammatory disease within the previous year. InLiletta was approved by the FDA. Liletta has a similar size and levonorgestrel release characteristics as Mirena, and is FDA-approved for three years of use following a study in which six women out of 1, conceived while using Dispsoitivo.
InBayer diapositivo, the maker of Mirena, was issued an FDA Warning Letter by the United States Food and Drug Administration for overstating the efficacy, minimizing the risks of use, and making “false or misleading presentations” about the device.
Mechanism of action Although the precise mechanism of action is not known, currently available IUCs work primarily by preventing sperm from fertilizing ova. Exposure to a foreign body causes a sterile inflammatory reaction in the intrauterine environment that is toxic to mirenna and ova and impairs implantation. In addition, ovulation is often impaired as a result of systemic absorption of levonorgestrel. Myths and misconceptions dispositio IUCs Myth: IUCs prevent fertilization and are true contraceptives.
Conclusions Active substances released from the IUD or IUS, together with products derived from the inflammatory reaction present in the luminal fluids of the genital tract, are toxic for spermatozoa and oocytes, preventing the encounter of healthy gametes and the formation of viable embryos.
The current data do not indicate that embryos are ,irena in IUD users at a rate comparable to that of nonusers. The common belief that the usual mechanism of action of IUDs in women is destruction of embryos in the uterus is not supported by empirical evidence. The bulk of the data indicate that interference with the reproductive process after fertilization has taken place is exceptional in the presence of a T-Cu or LNG-IUD and that the usual mechanism by which they prevent pregnancy in women is by preventing fertilization.
Mechanisms of action Thus, both clinical and experimental evidence suggests that IUDs can prevent and disrupt implantation. It is unlikely, however, that this is the main IUD mode of action, … The best evidence indicates that in IUD users it is unusual for embryos to reach the uterus. In conclusion, IUDs may exert their contraceptive action at different levels. Potentially, they interfere with sperm function and transport within the uterus and tubes.
It is difficult to determine whether fertilization of the oocyte is impaired by these compromised sperm. There is sufficient evidence to suggest that IUDs can prevent and disrupt implantation.
The extent to which this interference contributes to its contraceptive action is unknown. The data are scanty and the political consequences of resolving this issue interfere with comprehensive research. Summary IUDs that release copper or levonorgestrel are extremely effective contraceptives Both copper IUDs and levonorgestrel releasing IUSs may interfere with implantation, although this may not be the primary mechanism of action.
Mechanism of action The contraceptive action of all IUDs is mainly in the intrauterine cavity. Ovulation is not affected, and the IUD is not an abortifacient. Nonmedicated IUDs depend for contraception on the general reaction of the uterus to a foreign body. It is believed that this reaction, a sterile inflammatory response, produces tissue injury of a minor degree but sufficient enough to be spermicidal. Very few, if any, sperm reach the ovum in the fallopian tube.
The progestin-releasing IUD adds the endometrial action of the progestin to the foreign body reaction. The endometrium becomes decidualized with atrophy of the glands. Intrauterine devices Mechanisms of action The common belief that the usual mechanism of action of IUDs in women is destruction of embryos in the uterus is not supported by empirical evidence Because concern over mechanism of action represents a barrier to acceptance of this important and highly effective method for some women and some clinicians, it is important to point out that there is no evidence to suggest that the mechanism of action of IUDs is abortifacient.
DIU hormonal – Wikipedia, la enciclopedia libre
Therefore, fertilization does not occur and its main mechanism of action is also preconceptual. Less inflammation occurs within the uterus of LNG-IUS users, but the potent progestin effect thickens cervical mucus to impede sperm penetration and access to the upper genital track. Although the LNG-IUS also produces a thin, inactive endometrium, there is no evidence to suggest that this will prevent implantation, and the device should not be used for emergency contraception. From Wikipedia, the free encyclopedia.
This article is about hormone-based IUDs. For copper-based, see Copper IUDs. In Hatcher, Robert A. Contraceptive technology 20th revised ed. Archived 15 February at the Wayback Machine. BNF 69 69th ed. Archived from the original on 1 January Retrieved 1 January Archived from the original on 24 September Office Evaluation and Management of the Uterine Cavity.
Archived from the original on 5 November Archived PDF from the original on 13 December Retrieved 8 December International Drug Price Indicator Guide.
Expert Review of Medical Devices. Int J Gynaecol Obstet. The Cochrane Database of Systematic Reviews 1: New England Journal of Medicine. Archived from the original on 18 February Archived from the original on 19 July